O'Reilly Automotive Inc. Common Stock vs TG Therapeutics Inc — how do they compare? O'Reilly Automotive Inc. Common Stock trades at $86.45 (market cap $69.58B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: O'Reilly Automotive Inc. Common Stock is far larger — about 8.5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, O'Reilly Automotive Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| ORLY | TGTX | |
|---|---|---|
Market Cap | $69.58B | $8.16B |
Volume | 4,819,072 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $103.05 | $59.06 |
52-Week Low | $82.73 | $26.94 |
Enterprise Value | $78.90B | $8.37B |
Typical Hold Time | — | 16 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
O'Reilly Automotive sells automotive aftermarket parts, tools, supplies, equipment, and accessories. It serves both professional service providers and do-it-yourself customers through its store network.
Read more on ORLY →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →